See Treo Ventures’ activity on LinkedIn

View organization page for CVRx | Barostim, graphic

13,246 followers

10mo

We are excited to announce today that FDA has approved expanded labeling for Barostim, incorporating key long-term clinical data from the BeAT-HF randomized clinical trial. “We are very pleased to receive this important validation from FDA of the long-term results of the post-market phase of the BeAT-HF clinical trial and excited we can now share this data with physicians and patients,” said Nadim Yared, CVRx CEO Read the PR here: https://lnkd.in/ghM6tExk

CVRx receives FDA approval for expanded labeling of Barostim | CVRx

ir.cvrx.com

7 Comments

Wes Miller

Strategic Deal Management | Analytics | Strategic Pricing

10mo

Not surprising after seeing the win ratio, congrats CVRx team! FDA did a great job providing the idea and CVRx was already capturing the data to support. Great win for the patients.